(Q39582426)

13 September 2017

Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins (English)

1 reference

13 September 2017

0 references

9

William A Denny

1 reference

13 September 2017

Moana Tercel

1

1 reference

13 September 2017

Graham J Atwell

2

1 reference

13 September 2017

Shangjin Yang

3

1 reference

13 September 2017

Amir Ashoorzadeh

4

1 reference

13 September 2017

Ralph J Stevenson

5

1 reference

13 September 2017

K Jane Botting

6

1 reference

13 September 2017

Yongchuan Gu

7

1 reference

13 September 2017

Sunali Y Mehta

8

1 reference

13 September 2017

William R Wilson

10

1 reference

13 September 2017

Frederik B Pruijn

11

1 reference

13 September 2017

language of work or name

English

0 references

publication date

17 February 2011

1 reference

Angewandte Chemie International Edition

13 September 2017

4

1 reference

based on heuristic

inferred from page(s)

published in

0 references

volume

50

1 reference

13 September 2017

11

1 reference

13 September 2017

2606-2609

1 reference

Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).

13 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

Phase II trial of KW2189 in patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: the development of a highly potent prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

The impact of O2 availability on human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

Design of anticancer prodrugs for reductive activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

Exploiting tumour hypoxia in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201004456

21 January 2018

Identifiers

DOI

10.1002/ANIE.201004456

1 reference

13 September 2017

1 reference